A comfort comparison of travoprost BAK-free 0.004% versus latanoprost 0.005% in patients with primary open-angle glaucoma or ocular hypertension

被引:0
|
作者
Godfrey, David A. [1 ]
Peplinski, Lee S. [2 ]
Stewart, Jeanette A. [3 ]
Stewart, William C. [3 ]
机构
[1] Glaucoma Associates Texas, Dallas, TX USA
[2] Kentuckiana Inst Eye Res, Louisville, KY USA
[3] PRN Pharmaceut Res Network LLC, 5001 LBJ Freeway,Suite 700, Dallas, TX 75244 USA
来源
CLINICAL OPHTHALMOLOGY | 2009年 / 3卷
关键词
comfort; travoprost BAK-free; latanoprost; glaucoma; ocular hypertension;
D O I
暂无
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Purpose: To determine the short-term comfort after a single dose of travoprost BAK-free compared to latanoprost in primary open-angle glaucoma or ocular hypertensive patients. Design: Prospective, double-masked, randomized comparison of two separate active agents dosed once in opposite eyes. Methods: At Visit 1, qualified patients began a glaucoma medicine-free period for three days. At Visit 2, patients were randomly assigned to travoprost BAK-free or latanoprost in opposite eyes. Following dosing in each eye, patients completed a visual analog scale (VAS score, 0-100 mm) at specified time intervals and a comfort survey. Results: In 54 completed subjects, no difference existed five seconds after dosing, in comfort on the VAS between latanoprost (7.1 +/- 16.2 mm) and travoprost BAK-free (7.8 +/- 16.1 mm, P = 0.53). Also no differences existed between treatments following dosing for discomfort at individual timepoints past five seconds, peak discomfort or the time required to return to baseline comfort (P +/- 0.05). In addition, the comfort survey demonstrated no difference between products for burning, stinging, foreign body sensation, overall comfort and general acceptance between the products, both for absolute levels and changes from baseline (P +/- 0.05). Conclusion: Following a single instillation, both latanoprost and travoprost BAK-free exhibit similar comfort scores.
引用
收藏
页码:189 / 194
页数:6
相关论文
共 50 条
  • [21] Preservative-Free Latanoprost Eye Drops in Patients with Primary Open-Angle Glaucoma/Ocular Hypertension
    Sanford, Mark
    CLINICAL DRUG INVESTIGATION, 2014, 34 (07) : 521 - 528
  • [22] Ocular hypotensive efficacy of brimonidine 0.15% as adjunctive therapy with latanoprost 0.005% in patients with open-angle glaucoma or ocular hypertension
    Thomas Mundorf
    Robert J. Noecker
    Melissa Earl
    Advances in Therapy, 2007, 24 : 302 - 309
  • [23] Ocular hypotensive efficacy of brimonidine 0.15% as adjunctive therapy with latanoprost 0.005% in patients with open-angle glaucoma or ocular hypertension
    Mundorf, Thomas
    Noecker, Robert J.
    Earl, Melissa
    ADVANCES IN THERAPY, 2007, 24 (02) : 302 - 309
  • [24] Preservative-free versus preserved latanoprost eye drops in patients with open-angle glaucoma or ocular hypertension
    Aptel, Florent
    Choudhry, Reena
    Stalmans, Ingeborg
    CURRENT MEDICAL RESEARCH AND OPINION, 2016, 32 (08) : 1457 - 1463
  • [25] Diurnal IOP-lowering efficacy and safety of travoprost 0.004% compared with tafluprost 0.0015% in patients with primary open-angle glaucoma or ocular hypertension
    Schnober, Dietmar
    Hofmann, Gunter
    Maier, Hubert
    Scherzer, Maria-Luise
    Ogundele, Abayomi B.
    Jasek, Mark C.
    CLINICAL OPHTHALMOLOGY, 2010, 4 : 1459 - 1463
  • [26] Response to travoprost in black and nonblack patients with open-angle glaucoma or ocular hypertension
    Peter A. Netland
    Stella M. Robertson
    E. Kenneth Sullivan
    Lewis Silver
    Michael V. W. Bergamini
    Scott Krueger
    Alan L. Weiner
    Alberta A. Davis
    Advances in Therapy, 2003, 20 : 149 - 163
  • [27] Response to travoprost in black and nonblack patients with open-angle glaucoma or ocular hypertension
    Netland, PA
    Robertson, SM
    Sullivan, EK
    Silver, L
    Bergamini, MVW
    Krueger, S
    Weiner, AL
    Davis, AA
    ADVANCES IN THERAPY, 2003, 20 (03) : 149 - 163
  • [28] Effect of bimatoprost on patients with primary open-angle glaucoma or ocular hypertension who are nonresponders to latanoprost
    Gandolfi, SA
    Cimino, L
    OPHTHALMOLOGY, 2003, 110 (03) : 609 - 614
  • [29] Pharmacogenetic markers of treatment response to latanoprost in patients with primary open-angle glaucoma and ocular hypertension
    Velkovska, Makedonka Atanasovska
    Blagus, Tanja
    Goricar, Katja
    Cvenkel, Barbara
    Dolzan, Vita
    EUROPEAN JOURNAL OF HUMAN GENETICS, 2023, 31 : 639 - 639
  • [30] Evaluation of the efficacy and safety of latanoprost 0.005% without benzalkonium chloride and its noninferiority to latanoprost 0.005% with benzalkonium chloride in patients with open-angle glaucoma and ocular hypertension
    Wirta, David
    Malhotra, Rajan
    Peace, James
    Lee, Bridgitte Shen
    Ogundele, Abayomi
    Sall, Kenneth N.
    McMenemy, Matthew
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2019, 60 (09)